Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

United Health Products Expands Animal Testing for HemoStyp® in Support of PMA Application, Human Trials to Follow


Posted on: 01 May 18

HENDERSON, Nev., May 01, 2018 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is launching expanded and more robust animal testing for HemoStyp within the next two weeks. These tests are expected to take approximately two to three weeks to complete, following which the protocols for human pilot trials will be confirmed. The human pilot trials are expected to commence within three weeks of animal testing completion.  Both the expanded animal testing and human trials are being conducted to support the company’s HemoStyp PMA submission for internal surgical use and are being done in coordination with the FDA.

“After consulting with the FDA regarding our PMA application for HemoStyp, we will conduct expanded animal testing, following which our human pilot trial protocol will be confirmed,” said Douglas K. Beplate, CEO, UHP.  “We expect to complete both the expanded animal testing and human pilot trials within the next 14 weeks, following which we will present our findings to the FDA.”

About Premarket Approval (PMA): https://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/premarketsubmissions/premarketapprovalpma/

About United Health Products, Inc.

United Health Products develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its products, and expanding its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact: 877-358-3444/ IR Contact: Philippe Niemetz, PAN Consultants Ltd. 212-344-6464

GlobeNewswire
globenewswire.com

Last updated on: 01/05/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.